Pfizer Inc EV/EBITDA
Data as of September 29, 2026
EV/EBITDA
24.71
Enterprise Value
$225.68B
EBITDA (TTM)
$9.13B
Sector
Pharmaceuticals
How It's Calculated
24.71 = $225.68B ÷ $9.13B
What This Means
Pfizer Inc's EV/EBITDA of 24.7 is elevated, which can reflect growth expectations, scarce assets, or cyclical EBITDA.
About Pfizer Inc
Pfizer Inc (PFE) operates in the Pharmaceuticals sector, specifically in Pharmaceuticals. With a market capitalization of about $163.46B, it ranks as a large-cap stock — a major established company.
Shares recently traded near $28.72, within a 52-week range of $23.58 to $29.21 (-1.7% from the high, +21.8% from the low). Beta of 0.28 indicates relatively lower volatility versus the market.
Trailing profit margin is about 6.8%, signaling modest profitability that investors should weigh against growth plans.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Pfizer Inc, the ratio should be read with growth, capex needs, and cycle position in Pharmaceuticals. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Near 24.71x EV/EBITDA, Pfizer Inc (PFE) carries an elevated EV/EBITDA multiple that may embed growth expectations or scarcity within its peer set. Enterprise value of about $225.68B and EBITDA near $9.13B form the ratio — adjust for one-time items before treating the headline multiple as comparable.
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the PFE metrics hub for related valuation pages.
Sector Comparison
Among Pharmaceuticals names on our S&P 100 coverage, Pfizer Inc's EV/EBITDA of 24.71 can be compared with peers such as LLY (31.05), JNJ (21.42), MRK (43.42). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Pharmaceuticals stocks.
Key Takeaways
- PFE is grouped in the Pharmaceuticals sector for peer comparisons.
- Recent beta of 0.28 suggests lower-than-market price sensitivity.
- Trailing profit margin of 6.8% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for PFE.
Learn the full workflow
Compare PE with PB, PEG, EV/EBITDA, and market cap in one structured path.
Open the Stock Valuation hub →Other PFE Metrics
Frequently Asked Questions
What is PFE's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Pfizer Inc's ratio is about 24.71 — common for comparing leveraged companies in Pharmaceuticals.
Is 24.71 high or low vs peers?
Among Pharmaceuticals peers (e.g. MRK (43.42), LLY (31.05), JNJ (21.42)), PFE's 24.71 should be read with growth, capex, and debt levels.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →